Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
Inhibikase Therapeutics appointed Scott M. Wasserman, MD, to its Board of Directors effective October 19, 2026, while director Dennis Berman resigned concurrently. Dr. Wasserman is a cardiologist and CMO of Kailera Therapeutics, with prior leadership of cardiovascular and metabolic development at Amgen, where he led Repatha's global development and approvals and contributed to Evenity and Aimovig.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.